William Blair started coverage on shares of Guardant Health (NASDAQ:GH) in a report issued on Monday, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.
Separately, Bank of America started coverage on shares of Guardant Health in a report on Monday. They set a neutral rating and a $37.00 price objective on the stock.
GH traded up $0.22 during mid-day trading on Monday, reaching $32.81. 11,007 shares of the stock were exchanged, compared to its average volume of 1,302,050. Guardant Health has a 1 year low of $27.04 and a 1 year high of $44.25.
Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.